TY  - CONF

T1  - Zoledronic acid (4mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90mg) in patients with breast cancer and bone metastasis.

JO  - BREAST CANCER RESEARCH AND TREATMENT

PY  - 2002/12/01

AU  - Coleman RE

AU  - Rosen LS

AU  - Gordon D

AU  - Major P

AU  - Kaminski M

AU  - Apffelstaedt J

AU  - Howell A

AU  - Chen BL

AU  - Seaman JJ

ED  - 

VL  - 76

SP  - S95

EP  - S95

Y2  - 2025/10/10

ER  -